Key Takeaways
- Eli Lilly (LLY) is aggressively pursuing global dominance in the obesity medication market, having achieved top sales in several international countries and planning to submit its Orforglipron pill for approval across major markets within weeks.
- China's industrial sector showed robust growth in August, with crude iron ore production rising 8.8% to 81.63 million metric tons and copper output increasing 14.8% year-over-year to 1.301 million tons, yet the nation grapples with a rising youth jobless rate, which climbed to 18.9% (excluding students).
- Apple's (AAPL) iPhone sales in China experienced a notable 6% decline during the July-August period, contributing to an overall 2% drop in the country's smartphone sales.
- A significant hurdle for Eli Lilly's (LLY) international expansion is the prevalence of direct patient payments for obesity medications outside the United States, often without reimbursement, which could impact market penetration and access.
Eli Lilly's (LLY) Ambitious Global Obesity Strategy
Pharmaceutical giant Eli Lilly (LLY) is making significant strides in its international expansion of obesity medications, with its International President reporting the company as the leader in obesity drug sales in key markets including the UK, Italy, Spain, UAE, and Japan. The company aims to replicate its substantial success in the U.S. market on a global scale. A core component of this strategy involves replicating its successful U.S. consumer obesity approach in countries such as the UK, China, UAE, and Australia.
To bolster its presence in the crucial Chinese market, Eli Lilly (LLY) has announced a partnership with major telehealth platforms, Alibaba and JD, to enhance awareness and sales of its obesity drugs. Furthermore, the company is poised to submit its Orforglipron pill for approval in major global jurisdictions, including the United States, United Kingdom, European Union, Japan, and China, within weeks. While pursuing a new fast-track review process with the FDA for its obesity pill, the company's International President cautioned that approval cannot be guaranteed. A notable challenge in international markets is that most obesity medication expenses outside the U.S. are currently borne by patients without reimbursement, potentially influencing market dynamics.
Mixed Economic Signals Emerge from China
China's economy presented a mixed picture in August, with strong industrial output contrasting with persistent challenges in the labor market and consumer electronics. The country reported an 8.8% rise in crude iron ore production, reaching 81.63 million metric tons for August. Similarly, copper output saw a significant year-over-year increase of 14.8%, totaling 1.301 million tons in August. These figures suggest continued strength in China's heavy industry and manufacturing sectors.
However, the labor market continues to face headwinds, as China's youth jobless rate, excluding students, rose to 18.9% in August. This elevated unemployment rate among young people highlights ongoing structural issues and potential challenges for consumer confidence. Adding to the concerns regarding consumer demand, Apple's (AAPL) iPhone sales in China declined by 6% during the July-August period. This contributed to an overall 2% decrease in China's smartphone sales over the same two months.
Geopolitical Developments
In geopolitical news, Israeli Prime Minister Benjamin Netanyahu is scheduled to meet with U.S. President Donald Trump at the White House on September 29. This meeting is expected to cover a range of bilateral and regional issues. Separately, the Trump administration has reportedly cleared the first tranche of Ukraine arms aid that will be paid for by allied nations, signaling a new mechanism for international support to Ukraine.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.